Vascular Biogenics Ltd (VBLT)

[davidal66]

The company is not really blinded IMHO. One thing I think they must know at this juncture is the following: how many patients are on VB111/Avastin versus Avastin only. That would be an interesting statistic no matter what the final overall survival number is. If you have say twice as many patients still on VB111 as on Avastin only--this would strongly imply a tail of long term survivors. In the stellar phase II results, the VB111 high dose cohort only got like 3-4 infusions of VB111. I have to check that but I think thats right. So, they probably know how many VB111 infusions have been given to date and with some fancy math can track how the average number of VB111 infusions compares to the phase II trial.